Posted in | Nanomedicine | Nanobusiness

Tekmira’s Lipid Nanoparticle Technology Facilitates Alnylam’s Positive ALN-TTR02 Clinical Results

Tekmira Pharmaceuticals, a company specializing in RNA interference (RNAi) therapeutics, announced that Alnylam Pharmaceuticals has reported its Phase 1 clinical trial results for ALN-TTR02, an RNAi therapeutic that uses Tekmira's lipid nanoparticle delivery platform to target transthyretin (TTR) for TTR-mediated amyloidosis (ATTR) treatment.

ALN-TTR02 is produced by Tekmira Pharmaceuticals. Alnylam Pharmaceuticals presented the latest results at Boston University School of Medicine. The results demonstrated that ALN-TTR02 administration considerably lowered the serum levels of TTR proteins by about 94%. For a single dose, knockdown of the disease-causing TTR protein in ATTR was specific, quick, long-lasting, and based on the dosage.

Alnylam Pharmaceuticals recently announced the start of a Phase 2 clinical trial of ALN-TTR02 in patients having ATTR, with an objective to initiate a pivotal study in the fiscal year 2013. The commencement of the Phase 2 clinical trial of ALN-TTR02 generated a landmark payment to Tekmira Pharmaceuticals.

Tekmira Pharmaceuticals’ President and Chief Executive Officer, Dr. Mark J. Murray stated that these positive results on the Phase 1 clinical study of ALN-TTR02 further corroborate Tekmira Pharmaceuticals’ proven lipid nanoparticle delivery technology as the gold standard to make possible RNAi therapeutics that are in the company’s pipeline and those of its partners for a myriad of clinical indications.

Source: http://www.tekmirapharm.com

Will Soutter

Written by

Will Soutter

Will has a B.Sc. in Chemistry from the University of Durham, and a M.Sc. in Green Chemistry from the University of York. Naturally, Will is our resident Chemistry expert but, a love of science and the internet makes Will the all-rounder of the team. In his spare time Will likes to play the drums, cook and brew cider.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Soutter, Will. (2019, February 12). Tekmira’s Lipid Nanoparticle Technology Facilitates Alnylam’s Positive ALN-TTR02 Clinical Results. AZoNano. Retrieved on November 14, 2019 from https://www.azonano.com/news.aspx?newsID=25252.

  • MLA

    Soutter, Will. "Tekmira’s Lipid Nanoparticle Technology Facilitates Alnylam’s Positive ALN-TTR02 Clinical Results". AZoNano. 14 November 2019. <https://www.azonano.com/news.aspx?newsID=25252>.

  • Chicago

    Soutter, Will. "Tekmira’s Lipid Nanoparticle Technology Facilitates Alnylam’s Positive ALN-TTR02 Clinical Results". AZoNano. https://www.azonano.com/news.aspx?newsID=25252. (accessed November 14, 2019).

  • Harvard

    Soutter, Will. 2019. Tekmira’s Lipid Nanoparticle Technology Facilitates Alnylam’s Positive ALN-TTR02 Clinical Results. AZoNano, viewed 14 November 2019, https://www.azonano.com/news.aspx?newsID=25252.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit